Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ: GPCR )

30.10 -2.61 (-7.98%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 822,574
Open 33.08
Bid (Size) 29.99 (1)
Ask (Size) 31.06 (9)
Prev. Close 32.71
Today's Range 29.93 - 33.75
52wk Range 26.61 - 66.38
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
-25.48%
-25.48%
1 Month
-23.62%
-23.62%
3 Month
-23.12%
-23.12%
6 Month
-21.45%
-21.45%
1 Year
-41.41%
-41.41%

More News

Read More
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
From Structure Therapeutics Inc.
Via GlobeNewswire
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Via Benzinga
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
Via MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Via Investor's Business Daily
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Via Investor's Business Daily
Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday
Via Benzinga
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO
Via Investor's Business Daily
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Via MarketBeat
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
From Structure Therapeutics Inc.
Via GlobeNewswire
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
Via Investor's Business Daily
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
Via Investor's Business Daily
Structure Therapeutics Appoints Angus C. Russell to Board of Directors
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
3 Promising Biotech Stocks for the Long-Term: August 2024
Via InvestorPlace
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
3 Biotech Stocks That Could Make Your Summer Unforgettable
Via InvestorPlace
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
Via The Motley Fool
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
Via Investor's Business Daily
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.